GSK suspends dosing in Crohn's disease treatment trial

08/26/2013 | Reuters

GlaxoSmithKline said adverse events increased at a new higher dosage in a trial of vercirnon, an experimental treatment licensed from ChemoCentryx. The findings prompted GSK to suspend new patient recruitment and dosing pending further analysis in the Crohn's disease study. "The results from the SHIELD-1 study are clearly disappointing but we are committed to further explore the data to determine the way forward to help patients with this chronic debilitating gastrointestinal disease," a GSK official said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN